论文部分内容阅读
目的探讨新型降压药乌拉地尔（ＵＲＡ）对高血压患者血浆降钙素基因相关肽（ＣＧＲＰ）和内皮素（ＥＴ）含量的影响。方法采用放射免疫方法测定１５例高血压患者ＵＲＡ治疗前后血浆ＣＧＲＰ和ＥＴ含量变化。结果高血压患者血浆ＣＧＲＰ明显低于正常对照组（Ｐ＜００１）。血浆ＥＴ及ＥＴ／ＣＧＲＰ明显高于正常对照组（Ｐ＜００１）。经静脉ＵＲＡ治疗后５ｍｉｎ，高血压患者血浆ＣＧＲＰ明显升高（Ｐ＜００１），ＥＴ及ＥＴ／ＣＧＲＰ则明显降低（Ｐ＜００１）。结论ＣＧＲＰ与ＥＴ共同在高血压发病过程中起重要作用。ＵＲＡ可明显提高人体内ＣＧＲＰ水平，在降低血压的同时对ＥＴ有明显的拮抗效应。
Objective To investigate the effect of a new antihypertensive drug, Urapidil, on plasma calcitonin gene related peptide (CGRP) and endothelin (ET) levels in patients with essential hypertension. Methods The levels of plasma CGRP and ET in 15 hypertensive patients before and after URA treatment were measured by radioimmunoassay. Results Plasma levels of CGRP in patients with hypertension were significantly lower than those in the control group (P <001). Plasma ET and ET / CGRP levels were significantly higher than those in the normal control group (P <001). After 5 minutes of intravenous URA treatment, plasma CGRP was significantly higher in hypertensive patients (P <001), ET and ET / CGRP was significantly lower (P <001). Conclusions CGRP and ET play an important role in the pathogenesis of hypertension. URA can significantly increase the level of CGRP in the human body, while having a significant antagonistic effect on ET while lowering blood pressure.